BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 238] [Article Influence: 68.5] [Reference Citation Analysis]
Number Citing Articles
1 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
2 Choi YI, Jeong SH, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, So S, Lee JH, Jeong JY, Lee SM. Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea. Can J Infect Dis Med Microbiol. 2019;2019:9351801. [PMID: 31360270 DOI: 10.1155/2019/9351801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Guo CG, Jiang F, Cheung KS, Li B, Ooi PH, Leung WK. Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. J Antimicrob Chemother 2021:dkab415. [PMID: 34791274 DOI: 10.1093/jac/dkab415] [Reference Citation Analysis]
4 Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia. Biomedica 2019;39:125-34. [PMID: 31529855 DOI: 10.7705/biomedica.v39i3.4437] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Chen Z, Liu H, Zhang Y, Jin T, Hu J, Yang K. 13C-Urea Breath Test for the Diagnosis of H. pylori Infection in Patients after Partial Gastrectomy: A Systematic Review and Meta-Analysis. J Invest Surg 2021;:1-10. [PMID: 34493140 DOI: 10.1080/08941939.2021.1972185] [Reference Citation Analysis]
6 Kakiuchi T, Matsuo M, Endo H, Nakayama A, Sato K, Takamori A, Sasaki K, Takasaki M, Hara M, Sakata Y, Okuda M, Kikuchi S, Eguchi Y, Takahashi H, Anzai K, Fujimoto K. A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report. J Gastroenterol 2019;54:699-707. [DOI: 10.1007/s00535-019-01559-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
7 Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. J Clin Microbiol 2021;59:e03040-20. [PMID: 33536295 DOI: 10.1128/JCM.03040-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
9 Miendje Deyi VY, Lare MS, Burette A, Ntounda R, Elkilic O, Cadranel S, Bontems P, Hallin M. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium. Diagnostic Microbiology and Infectious Disease 2019;95:114875. [DOI: 10.1016/j.diagmicrobio.2019.114875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Wang S, Chen Z, Zhu S, Lu H, Peng D, Soutto M, Naz H, Peek R Jr, Xu H, Zaika A, Xu Z, El-Rifai W. PRDX2 protects against oxidative stress induced by H. pylori and promotes resistance to cisplatin in gastric cancer. Redox Biol 2020;28:101319. [PMID: 31536951 DOI: 10.1016/j.redox.2019.101319] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
11 Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714. [PMID: 32533599 DOI: 10.1111/hel.12714] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth S, Binh TT, Sokhem S, Tri TD, Ngov S, Tung PH, Thuan NPM, Truc TC, Phuc BH, Matsumoto T, Fauzia KA, Akada J, Trang TTH, Yamaoka Y. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates. J Clin Med 2019;8:E858. [PMID: 31208076 DOI: 10.3390/jcm8060858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
13 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Reference Citation Analysis]
14 Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infect Dis 2021;21:642. [PMID: 34218802 DOI: 10.1186/s12879-021-06356-5] [Reference Citation Analysis]
15 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
16 Argueta EA, Moss SF. Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment. Aliment Pharmacol Ther 2019;50:331-2. [DOI: 10.1111/apt.15302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
18 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Jubair N, Rajagopal M, Chinnappan S, Abdullah NB, Fatima A. Review on the Antibacterial Mechanism of Plant-Derived Compounds against Multidrug-Resistant Bacteria (MDR). Evid Based Complement Alternat Med 2021;2021:3663315. [PMID: 34447454 DOI: 10.1155/2021/3663315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Reference Citation Analysis]
21 Argueta EA, Alsamman MA, Moss SF, D'Agata EMC. Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology 2021;160:2181-2183.e1. [PMID: 33577874 DOI: 10.1053/j.gastro.2021.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
22 Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc 2021:S0929-6646(21)00106-6. [PMID: 33745813 DOI: 10.1016/j.jfma.2021.03.001] [Reference Citation Analysis]
23 Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH, Kim HS, Kim TH, Shim KN, Chung IK, Park MI, Choi IJ, Kim JH, Kim BW, Baik GH, Han SW, Seo HE, Jung WT, Hwan Oh J, Kim SG, Lee JH, Park SK, Park BJ, Yang BR, Lee J, Kim JG. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success. Helicobacter. 2019;24:e12646. [PMID: 31368629 DOI: 10.1111/hel.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
24 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021:gutjnl-2021-324032. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Argueta EA, Moss SF. Treatment of Helicobacter pylori. Current Opinion in Gastroenterology 2019;35:544-50. [DOI: 10.1097/mog.0000000000000578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
28 Kumar P, Pletzer D, Haney EF, Rahanjam N, Cheng JTJ, Yue M, Aljehani W, Hancock REW, Kizhakkedathu JN, Straus SK. Aurein-Derived Antimicrobial Peptides Formulated with Pegylated Phospholipid Micelles to Target Methicillin-Resistant Staphylococcus aureus Skin Infections. ACS Infect Dis 2019;5:443-53. [DOI: 10.1021/acsinfecdis.8b00319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
29 Bricker-Ford R. Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. J Pharm Pract 2021;:8971900211033143. [PMID: 34269127 DOI: 10.1177/08971900211033143] [Reference Citation Analysis]
30 Morilla AM, Álvarez-Argüelles ME, Duque JM, Armesto E, Villar H, Melón S. Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. Gastroenterol Hepatol 2019;42:476-85. [PMID: 31324461 DOI: 10.1016/j.gastrohep.2019.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
31 Guo C, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK. Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology 2021;19:314-322.e2. [DOI: 10.1016/j.cgh.2020.03.071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
32 Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Front Med (Lausanne) 2021;8:713908. [PMID: 34660627 DOI: 10.3389/fmed.2021.713908] [Reference Citation Analysis]
33 Gudra D, Pupola D, Skenders G, Leja M, Radovica-Spalvina I, Gorskis H, Vangravs R, Fridmanis D. Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event. Helicobacter 2020;25:e12748. [PMID: 32776403 DOI: 10.1111/hel.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Liu DS, Wang YH, Zhu ZH, Zhang SH, Zhu X, Wan JH, Lu NH, Xie Y. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control 2019;8:192. [PMID: 31798838 DOI: 10.1186/s13756-019-0632-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
36 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021;21:95. [PMID: 33653284 DOI: 10.1186/s12876-021-01680-1] [Reference Citation Analysis]
38 Rahman MM, Tikhomirova A, Modak JK, Hutton ML, Supuran CT, Roujeinikova A. Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS1 and 26695. Gut Pathog 2020;12:20. [PMID: 32318117 DOI: 10.1186/s13099-020-00358-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
39 Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385-1394. [PMID: 31020673 DOI: 10.1111/apt.15273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
40 Hu Y, Ouyang Y, Zhu Y, Lu NH. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Helicobacter 2021;26:e12784. [PMID: 33534148 DOI: 10.1111/hel.12784] [Reference Citation Analysis]
41 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
42 Das S, Das MK, Das R, Gehlot V, Mahant S, Mazumder PM, Das S, Falls N, Kumar V. Isolation, characterization of Berberine from Berberis aristata DC for eradication of resistant Helicobacter pylori. Biocatalysis and Agricultural Biotechnology 2020;26:101622. [DOI: 10.1016/j.bcab.2020.101622] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
43 Liu J, Yu R, Jia J, Gu W, Zhang H. Assignment of Absolute Configurations of Two Promising Anti-Helicobacter pylori Agents from the Marine Sponge-Derived Fungus Aspergillus niger L14. Molecules 2021;26:5061. [PMID: 34443650 DOI: 10.3390/molecules26165061] [Reference Citation Analysis]
44 Krzyżek P, Grande R. Transformation of Helicobacter pylori into Coccoid Forms as a Challenge for Research Determining Activity of Antimicrobial Substances. Pathogens 2020;9:E184. [PMID: 32143312 DOI: 10.3390/pathogens9030184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
45 Hulten KG, Lamberth LB, Kalfus IN, Graham DY. National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial. Gastroenterology 2021;161:342-344.e1. [PMID: 33798524 DOI: 10.1053/j.gastro.2021.03.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
47 Park JY, Herrero R. Recent progress in gastric cancer prevention. Best Pract Res Clin Gastroenterol 2021;50-51:101733. [PMID: 33975687 DOI: 10.1016/j.bpg.2021.101733] [Reference Citation Analysis]
48 Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
49 Rezaei S, Talebi Bezmin Abadi A, Mohabatti Mobarez A. Metronidazole-resistant Helicobacter pylori isolates without rdxA mutations obtained from Iranian dyspeptic patients. New Microbes New Infect 2020;34:100636. [PMID: 31993205 DOI: 10.1016/j.nmni.2019.100636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
50 Arj A, Mollaei M, Razavizadeh M, Moraveji A. The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication. J Res Pharm Pract 2020;9:101-5. [PMID: 33102384 DOI: 10.4103/jrpp.JRPP_19_86] [Reference Citation Analysis]
51 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Reference Citation Analysis]
52 Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
53 Peng C, Hu Y, Ge ZM, Zou QM, Lyu NH. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med 2019;5:243-51. [PMID: 32055783 DOI: 10.1016/j.cdtm.2019.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
54 Padole P, Ranjan P, Sachdeva M, Kumar M. Role of Helicobacter pylori eradication in patients with functional dyspepsia. Indian J Gastroenterol 2021. [PMID: 34708338 DOI: 10.1007/s12664-021-01195-3] [Reference Citation Analysis]
55 Loor A, Dumitrascu DL, Surdea-Blaga T, Leucuta DC, David L. Helicobacter pylori infection and positive Rome IV criteria for functional dyspepsia in Romanian medical students. J Med Life 2021;14:492-7. [PMID: 34621372 DOI: 10.25122/jml-2021-0163] [Reference Citation Analysis]
56 Sholeh M, Maleki F, Krutova M, Bavari S, Golmoradi R, Sadeghifard N, Amiriani T, Kouhsari E. The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis. Helicobacter 2020;25:e12730. [PMID: 32705749 DOI: 10.1111/hel.12730] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Botija G, García Rodríguez C, Recio Linares A, Campelo Gutiérrez C, Pérez-Fernández E, Barrio Merino A. [Antibiotic resistances and eradication rates in Helicobacter pylori infection]. An Pediatr (Engl Ed) 2020:S1695-4033(20)30448-3. [PMID: 33334694 DOI: 10.1016/j.anpedi.2020.10.006] [Reference Citation Analysis]
58 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
59 Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z, Zhao S, Zhang Y, Song C, Xie Y. Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis. Helicobacter 2021;:e12839. [PMID: 34318971 DOI: 10.1111/hel.12839] [Reference Citation Analysis]
60 Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44-53. [PMID: 30998990 DOI: 10.1053/j.gastro.2019.04.011] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 30.0] [Reference Citation Analysis]
61 Tang X, Shen Y, Hu R, Yang T, Benghezal M, Li H, Tang H. Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori. Helicobacter 2020;25:e12703. [PMID: 32453910 DOI: 10.1111/hel.12703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Salehi N, Attaran B, Zare-Mirakabad F, Ghadiri B, Esmaeili M, Shakaram M, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains. Helicobacter 2020;25:e12731. [PMID: 32794288 DOI: 10.1111/hel.12731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
64 Veliev AM, Maev IV, Andreev DN, Dicheva DT, Zaborovskii AV, Lobanova EG, Bektemirova LG. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease]. Ter Arkh 2019;91:28-33. [PMID: 32598751 DOI: 10.26442/00403660.2019.08.000382] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine (Lond) 2020;15:527-42. [PMID: 32028847 DOI: 10.2217/nnm-2019-0329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
66 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
67 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
68 Beer A, Hudler H, Hader M, Kundi M, Hudler S, Täuber V, Schachner H, Gruber S, Hirschl AM, Kain R, Makristathis A. Apparent intracellular Helicobacter pylori detected by immunohistochemistry - the missing link in eradication failure. Clin Infect Dis 2020:ciaa839. [PMID: 32569354 DOI: 10.1093/cid/ciaa839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
69 Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux PA, Vasseur P, Thiebault Q, Lefèvre C, de Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C. Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay. J Clin Microbiol 2020;58:e01787-19. [PMID: 31996442 DOI: 10.1128/JCM.01787-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
70 Mehrotra T, Devi TB, Kumar S, Talukdar D, Karmakar SP, Kothidar A, Verma J, Kumari S, Alexander SM, Retnakumar RJ, Devadas K, Ray A, Mutreja A, Nair GB, Chattopadhyay S, Das B. Antimicrobial resistance and virulence in Helicobacter pylori: Genomic insights. Genomics 2021;113:3951-66. [PMID: 34619341 DOI: 10.1016/j.ygeno.2021.10.002] [Reference Citation Analysis]
71 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
72 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Qin Y, Lao YH, Wang H, Zhang J, Yi K, Chen Z, Han J, Song W, Tao Y, Li M. Combatting Helicobacter pylori with oral nanomedicines. J Mater Chem B 2021;9:9826-38. [PMID: 34854456 DOI: 10.1039/d1tb02038b] [Reference Citation Analysis]
74 Akar M, Aydın F, Kayman T, Abay S, Karakaya E. Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing? Turk J Med Sci 2021;51:1445-64. [PMID: 33631868 DOI: 10.3906/sag-2101-69] [Reference Citation Analysis]
75 Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, Song Y, Li X, Graham DY, Lu H. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol 2019;12:1756284819874922. [PMID: 31523279 DOI: 10.1177/1756284819874922] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
76 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 De Leo AN, Bates JE, Lockney NA, Mendenhall NP, Shaikh ME, Morris CG, Hoppe BS. Radiotherapy in Early-stage Gastric MALT: Improved Survival Without Increased Cardiac Death. Am J Clin Oncol 2020;43:770-5. [PMID: 32841963 DOI: 10.1097/COC.0000000000000747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Li B, Rong Q, Du Y, Zhang R, Li J, Tong X, Geng L, Zhang Y. Regulation of β1-integrin in autophagy and apoptosis of gastric epithelial cells infected with Helicobacter pylori. World J Microbiol Biotechnol 2021;38:12. [PMID: 34873651 DOI: 10.1007/s11274-021-03199-9] [Reference Citation Analysis]
79 Ibrahim KA, Helmy OM, Kashef MT, Elkhamissy TR, Ramadan MA. Identification of Potential Drug Targets in Helicobacter pylori Using In Silico Subtractive Proteomics Approaches and Their Possible Inhibition through Drug Repurposing. Pathogens 2020;9:E747. [PMID: 32932580 DOI: 10.3390/pathogens9090747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
80 Pomari E, Ursini T, Silva R, Leonardi M, Ligozzi M, Angheben A. Concomitant Infection of Helicobacter pylori and Intestinal Parasites in Adults Attending a Referral Centre for Parasitic Infections in North Eastern Italy. J Clin Med 2020;9:E2366. [PMID: 32722134 DOI: 10.3390/jcm9082366] [Reference Citation Analysis]
81 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H. Early genetic diagnosis of clarithromycin resistance in Helicobacter pyloriWorld J Gastroenterol 2021; 27(24): 3595-3608 [PMID: 34239272 DOI: 10.3748/wjg.v27.i24.3595] [Reference Citation Analysis]
83 Baccani I, Faraoni P, Marini M, Gnerucci A, Orsini B, Pecile P, Romano G, Fusi F, Rossolini GM, Antonelli A. Synergistic effect of photodynamic therapy at 400 nm and doxycycline against Helicobacter pylori. Future Microbiol 2019;14:1199-205. [PMID: 31625444 DOI: 10.2217/fmb-2019-0129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
85 Kittisenachai S, Rojpibulstit P, Vilaichone RK, Gamnarai P, Phaonakrop N, Suealek N. FBPAII and rpoBC, the Two Novel Secreted Proteins Identified by the Proteomic Approach from a Comparative Study between Antibiotic-Sensitive and Antibiotic-Resistant Helicobacter pylori-Associated Gastritis Strains. Infect Immun 2021;89:e00053-21. [PMID: 33782154 DOI: 10.1128/IAI.00053-21] [Reference Citation Analysis]
86 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Reference Citation Analysis]
87 Nikbazm R, Rahimi Z, Moradi Y, Alipour M, Shidfar F. The effect of cranberry supplementation on Helicobacter pylori eradication in H. pylori positive subjects: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2021;:1-10. [PMID: 34670631 DOI: 10.1017/S0007114521004256] [Reference Citation Analysis]
88 Palmitessa V, Monno R, Panarese A, Cuppone R, Burattini O, Marangi S, Curlo M, Fumarola L, Petrosillo A, Parisi A, Capozzi L, Bianco A, Lippolis A. Evaluation of Antibiotic Resistance of Helicobacter pylori Strains Isolated in Bari, Southern Italy, in 2017-2018 by Phenotypic and Genotyping Methods. Microb Drug Resist 2020;26:909-17. [PMID: 32101078 DOI: 10.1089/mdr.2019.0262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
90 Xie M, Li Q, Zhang B, Zhang Q, Tian QJ, Liu H, Zang YJ, Rao W. Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients. Helicobacter 2021;26:e12791. [PMID: 33600067 DOI: 10.1111/hel.12791] [Reference Citation Analysis]
91 Quigley EMM, Gajula P. Recent advances in modulating the microbiome. F1000Res 2020;9:F1000 Faculty Rev-46. [PMID: 32047611 DOI: 10.12688/f1000research.20204.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
92 Maev IV, Andreev DN, Govorun VM, Ilina EN, Kucheryavyy YA, Oganesian TS, Melnikova EV, Zayratyants OV, Parfenova TV, Dzhedzheia LV, Kirillova NV, Maevskaya EA, Fomenko AK, Lobanova EG, Zaborovskii AV, Kriukov KA. [Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]. Ter Arkh 2020;92:24-8. [PMID: 33346458 DOI: 10.26442/00403660.2020.08.000761] [Reference Citation Analysis]
93 Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek RM Jr, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol 2021;59:e03203-20. [PMID: 33692136 DOI: 10.1128/JCM.03203-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
95 Sayed IM, Sahan AZ, Venkova T, Chakraborty A, Mukhopadhyay D, Bimczok D, Beswick EJ, Reyes VE, Pinchuk I, Sahoo D, Ghosh P, Hazra TK, Das S. Helicobacter pylori infection downregulates the DNA glycosylase NEIL2, resulting in increased genome damage and inflammation in gastric epithelial cells. J Biol Chem 2020;295:11082-98. [PMID: 32518160 DOI: 10.1074/jbc.RA119.009981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
96 González A, Casado J, Chueca E, Salillas S, Velázquez-Campoy A, Espinosa Angarica V, Bénejat L, Guignard J, Giese A, Sancho J, Lehours P, Lanas Á. Repurposing Dihydropyridines for Treatment of Helicobacter pylori Infection. Pharmaceutics 2019;11:E681. [PMID: 31847484 DOI: 10.3390/pharmaceutics11120681] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
97 Zhou B, Chen L, Li B, Wan L, Ai Y. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis. Helicobacter 2019;24. [DOI: 10.1111/hel.12651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
98 Wang A, Yerxa J, Agarwal S, Turner MC, Schroder V, Youngwirth LM, Lagoo-Deenadayalan S, Pappas TN. Surgical management of peptic ulcer disease. Curr Probl Surg 2020;57:100728. [PMID: 32138833 DOI: 10.1016/j.cpsurg.2019.100728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
99 Hu Q, Peng Z, Li L, Zou X, Xu L, Gong J, Yi P. The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol 2019;10:1694. [PMID: 32116685 DOI: 10.3389/fphar.2019.01694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
100 Luong HX, Thanh TT, Tran TH. Antimicrobial peptides - Advances in development of therapeutic applications. Life Sci 2020;260:118407. [PMID: 32931796 DOI: 10.1016/j.lfs.2020.118407] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
101 Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020;15:1185-96. [PMID: 32954842 DOI: 10.2217/fmb-2020-0084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03338-2. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Reference Citation Analysis]
103 Maroney MJ, Ciurli S. Nickel as a virulence factor in the Class I bacterial carcinogen, Helicobacter pylori. Semin Cancer Biol 2021:S1044-579X(21)00110-3. [PMID: 33865991 DOI: 10.1016/j.semcancer.2021.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2021;:1-8. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Boltin D, Ashorov O, Benejat L, Hamouda D, Belfer RG, Niv Y, Dickman R, Perets TT. Novel high resolution melt curve assay for the analysis of predominance of Helicobacter pylori clarithromycin resistance. Pathogens and Disease 2019;77:ftz042. [DOI: 10.1093/femspd/ftz042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kumar S, Metz DC, Ellenberg S, Kaplan DE, Goldberg DS. Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study.Gastroenterology. 2020;158:527-536.e7. [PMID: 31654635 DOI: 10.1053/j.gastro.2019.10.019] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 18.0] [Reference Citation Analysis]
107 Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T, Chen Z. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infect Drug Resist 2021;14:535-45. [PMID: 33603417 DOI: 10.2147/IDR.S287631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
109 Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YAA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S, Yamaoka Y. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel) 2020;12:E473. [PMID: 32722296 DOI: 10.3390/toxins12080473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
110 Wang X, Wang B, Gao W, An Y, Dong G, Jia J, Yang Q. Helicobacter pylori inhibits autophagic flux and promotes its intracellular survival and colonization by down-regulating SIRT1. J Cell Mol Med 2021;25:3348-60. [PMID: 33641223 DOI: 10.1111/jcmm.16411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
111 Kenyon C. Population-level macrolide consumption is associated with clarithromycin resistance in Helicobacter pylori: An ecological analysis. Int J Infect Dis 2019;85:67-9. [PMID: 31150843 DOI: 10.1016/j.ijid.2019.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. Management of Helicobacter pylori infection in the pediatric age. An Pediatr (Engl Ed) 2021;95:383.e1-9. [PMID: 34642127 DOI: 10.1016/j.anpede.2021.05.004] [Reference Citation Analysis]
113 Beheshtirouy S, Eyvazi S, Tarhriz V. Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients. J Gastrointest Cancer 2021;52:207-11. [PMID: 32130658 DOI: 10.1007/s12029-020-00386-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Cui R, Song Z, Suo B, Tian X, Xue Y, Meng L, Niu Z, Jin Z, Zhang H, Zhou L. Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori. Infect Drug Resist 2021;14:1747-56. [PMID: 34012273 DOI: 10.2147/IDR.S305996] [Reference Citation Analysis]
115 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of 3-Bromopyruvate, an Anticancer Compound, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Cancers (Basel) 2019;11:E229. [PMID: 30781380 DOI: 10.3390/cancers11020229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
116 Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2021:gutjnl-2021-326170. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Reference Citation Analysis]
117 Dos Santos Viana I, Cordeiro Santos ML, Santos Marques H, Lima de Souza Gonçalves V, Bittencourt de Brito B, França da Silva FA, Oliveira E Silva N, Dantas Pinheiro F, Fernandes Teixeira A, Tanajura Costa D, Oliveira Souza B, Lima Souza C, Vasconcelos Oliveira M, Freire de Melo F. Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape. Expert Rev Vaccines 2021;20:989-99. [PMID: 34139141 DOI: 10.1080/14760584.2021.1945450] [Reference Citation Analysis]
118 Huang Y, Hang X, Jiang X, Zeng L, Jia J, Xie Y, Li F, Bi H. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori. Antimicrob Agents Chemother. 2019;63. [PMID: 30936098 DOI: 10.1128/aac.00004-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
119 Zhou Q, Xue B, Gu R, Li P, Gu Q. Lactobacillus plantarum ZJ316 Attenuates Helicobacter pylori-Induced Gastritis in C57BL/6 Mice. J Agric Food Chem 2021;69:6510-23. [PMID: 34096709 DOI: 10.1021/acs.jafc.1c01070] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Opekun AR, Zierold C, Rode A, Blocki FA, Fiorini G, Saracino IM, Vaira D, Sutton FM. Clinical Performance of the Automated LIAISON® Meridian H. pylori SA Stool Antigen Test. Biomed Res Int 2020;2020:7189519. [PMID: 32280698 DOI: 10.1155/2020/7189519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
122 Liang CM, Hsu CH, Chung CH, Chen CY, Wang LY, Hsu SD, Chang PK, Hong ZJ, Chien WC, Hu JM. Risk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan. Int J Environ Res Public Health 2020;17:E3737. [PMID: 32466223 DOI: 10.3390/ijerph17103737] [Reference Citation Analysis]
123 Du S, Li Y, Su Z, Shi X, Johnson NL, Li P, Zhang Y, Zhang Q, Wen L, Li K, Chen Y, Zhang X, Fei Y, Ding X. Index-based dietary patterns in relation to gastric cancer risk: a systematic review and meta-analysis. Br J Nutr 2020;123:964-74. [PMID: 31767045 DOI: 10.1017/S0007114519002976] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
124 Ye L, Zhang J, Xiao W, Liu S. Efficacy and mechanism of actions of natural antimicrobial drugs. Pharmacol Ther 2020;216:107671. [PMID: 32916205 DOI: 10.1016/j.pharmthera.2020.107671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Choi YI, Lee SM, Chung JW, Kim KO, Kwon KA, Kim YJ, Kim JH, Lee SM, Jeong JY, Park DK. Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Helicobacter Eradication in Korea: An In Vitro Culture-Based Study. Antibiotics (Basel) 2021;10:1242. [PMID: 34680822 DOI: 10.3390/antibiotics10101242] [Reference Citation Analysis]
126 Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, Yang Q, Yu X, Lyu Z, Wu J, Guo H, Leung WK, Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother 2020;75:3391-4. [PMID: 32785699 DOI: 10.1093/jac/dkaa315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
127 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
128 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Grande R, Sisto F, Puca V, Carradori S, Ronci M, Aceto A, Muraro R, Mincione G, Scotti L. Antimicrobial and Antibiofilm Activities of New Synthesized Silver Ultra-NanoClusters (SUNCs) Against Helicobacter pylori. Front Microbiol 2020;11:1705. [PMID: 32849359 DOI: 10.3389/fmicb.2020.01705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
130 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
131 Zhao M, Jiang Y, Chen Z, Fan Z, Jiang Y. Traditional Chinese medicine for Helicobacter pylori infection: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24282. [PMID: 33546052 DOI: 10.1097/MD.0000000000024282] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Huang JG, Lim SYS, Aw MM, Quak SH. Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort. Helicobacter 2021;:e12868. [PMID: 34958710 DOI: 10.1111/hel.12868] [Reference Citation Analysis]
134 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
135 Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond) 2020;52:381-90. [PMID: 31900002 DOI: 10.1080/23744235.2019.1708454] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Mégraud F. Antibiotic Resistance Is the Key Element in Treatment of Helicobacter pylori Infection. Gastroenterology 2018;155:1300-2. [DOI: 10.1053/j.gastro.2018.10.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
137 Tacconelli E. Linking infection control to clinical management of infections to overcome antimicrobial resistance. J Hosp Infect 2021;114:1-9. [PMID: 33965455 DOI: 10.1016/j.jhin.2021.04.030] [Reference Citation Analysis]
138 Kageyama C, Sato M, Sakae H, Obayashi Y, Kawahara Y, Mima T, Matsushita O, Yokota K, Mizuno M, Okada H. Increase in antibiotic resistant Helicobacter pylori in a University Hospital in Japan. Infect Drug Resist 2019;12:597-602. [PMID: 30881065 DOI: 10.2147/IDR.S196452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
139 Bhat S, Nunes D. Pharmacist-Managed Helicobacter pylori Treatment Service Within a Gastroenterology Clinic: Workflow and Real-World Experiences. Ann Pharmacother 2021;:10600280211021501. [PMID: 34049441 DOI: 10.1177/10600280211021501] [Reference Citation Analysis]
140 Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1450-6. [PMID: 33217029 DOI: 10.1111/jgh.15352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Lettl C, Schindele F, Testolin G, Bär A, Rehm T, Brönstrup M, Schobert R, Bilitewski U, Haas R, Fischer W. Inhibition of Type IV Secretion Activity and Growth of Helicobacter pylori by Cisplatin and Other Platinum Complexes. Front Cell Infect Microbiol 2020;10:602958. [PMID: 33392108 DOI: 10.3389/fcimb.2020.602958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Gollapalli P, G TS, H M, Shetty P, N SK. Network topology analysis of essential genes interactome of Helicobacter pylori to explore novel therapeutic targets. Microb Pathog 2021;158:105059. [PMID: 34157412 DOI: 10.1016/j.micpath.2021.105059] [Reference Citation Analysis]
143 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
144 Brennan D, O’morain C, Mcnamara D, Smith SM. Molecular Detection of Antibiotic-Resistant Helicobacter pylori. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 29-36. [DOI: 10.1007/978-1-0716-1302-3_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Cunha ES, Chen X, Sanz-Gaitero M, Mills DJ, Luecke H. Cryo-EM structure of Helicobacter pylori urease with an inhibitor in the active site at 2.0 Å resolution. Nat Commun 2021;12:230. [PMID: 33431861 DOI: 10.1038/s41467-020-20485-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
146 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
149 Graham DY. Molecular-based Helicobacter pylori Susceptibility Testing Is Almost Ready for Prime Time. Gastroenterology 2021;160:1936-7. [PMID: 33647279 DOI: 10.1053/j.gastro.2021.02.057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
150 Ailloud F, Estibariz I, Suerbaum S. Evolved to vary: genome and epigenome variation in the human pathogen Helicobacter pylori. FEMS Microbiol Rev 2021;45:fuaa042. [PMID: 32880636 DOI: 10.1093/femsre/fuaa042] [Reference Citation Analysis]
151 White B, Sterrett JD, Grigoryan Z, Lally L, Heinze JD, Alikhan H, Lowry CA, Perez LJ, DeSipio J, Phadtare S. Characterization of gut microbiome and metabolome in Helicobacter pylori patients in an underprivileged community in the United States. World J Gastroenterol 2021; 27(33): 5575-5594 [PMID: 34588753 DOI: 10.3748/wjg.v27.i33.5575] [Reference Citation Analysis]
152 Bustamante-Rengifo JA, Astudillo-Hernández M, Del Pilar Crespo-Ortiz M. Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis. Curr Microbiol 2021;78:3351-71. [PMID: 34251513 DOI: 10.1007/s00284-021-02604-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Woo HJ, Yang JY, Lee P, Kim JB, Kim SH. Zerumbone Inhibits Helicobacter pylori Urease Activity. Molecules 2021;26:2663. [PMID: 34062878 DOI: 10.3390/molecules26092663] [Reference Citation Analysis]
154 Gravina AG, Priadko K, Granata L, Facchiano A, Scidà G, Cerbone R, Ciamarra P, Romano M. Single Capsule Bismuth Quadruple Therapy for Eradication of H. pylori Infection: A Real-Life Study. Front Pharmacol 2021;12:667584. [PMID: 33995097 DOI: 10.3389/fphar.2021.667584] [Reference Citation Analysis]
155 Miftahussurur M, Fauzia KA, Nusi IA, Setiawan PB, Syam AF, Waskito LA, Doohan D, Ratnasari N, Khomsan A, Adnyana IK, Akada J, Yamaoka Y. E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study. BMC Res Notes 2020;13:22. [PMID: 31924273 DOI: 10.1186/s13104-019-4877-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
156 Dewayani A, Fauzia KA, Alfaray RI, Waskito LA, Doohan D, Rezkitha YAA, Abdurachman A, Kobayashi T, I'tishom R, Yamaoka Y, Miftahussurur M. The Roles of IL-17, IL-21, and IL-23 in the Helicobacter pylori Infection and Gastrointestinal Inflammation: A Review. Toxins (Basel) 2021;13:315. [PMID: 33924897 DOI: 10.3390/toxins13050315] [Reference Citation Analysis]
157 Liyen Cartelle A, Uy PP, Koehler TE, Yap JEL. Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice. Cureus 2020;12:e12309. [PMID: 33520508 DOI: 10.7759/cureus.12309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
159 Mashak Z, Jafariaskari S, Alavi I, Sakhaei Shahreza M, Safarpoor Dehkordi F. Phenotypic and Genotypic Assessment of Antibiotic Resistance and Genotyping of vacA, cagA, iceA, oipA, cagE, and babA2 Alleles of Helicobacter pylori Bacteria Isolated from Raw Meat. Infect Drug Resist 2020;13:257-72. [PMID: 32099418 DOI: 10.2147/IDR.S233612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
160 Ji CR, Liu J, Li YY, Guo CG, Qu JY, Zhang Y, Zuo X. Safety of furazolidone-containing regimen in Helicobacter pylori infection: a systematic review and meta-analysis. BMJ Open 2020;10:e037375. [PMID: 33077561 DOI: 10.1136/bmjopen-2020-037375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis. Helicobacter 2021;26:e12816. [PMID: 34002433 DOI: 10.1111/hel.12816] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases 2021; 9(1): 133-147 [PMID: 33511178 DOI: 10.12998/wjcc.v9.i1.133] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Tang X, Chen X, Shen Y, Yang T, Hu R, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population. Future Microbiol 2020;15:1353-61. [PMID: 32900223 DOI: 10.2217/fmb-2020-0206] [Reference Citation Analysis]
164 Damale MG, Patil RB, Ansari SA, Alkahtani HM, Almehizia AA, Shinde DB, Arote R, Sangshetti J. Molecular docking, pharmacophore based virtual screening and molecular dynamics studies towards the identification of potential leads for the management of H. pylori. RSC Adv 2019;9:26176-208. [DOI: 10.1039/c9ra03281a] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
165 Yan J, Peng C, Chen P, Zhang W, Jiang C, Sang S, Zhu W, Yuan Y, Hong Y, Yao M. In-vitro anti-Helicobacter pylori activity and preliminary mechanism of action of Canarium album Raeusch. fruit extracts. J Ethnopharmacol 2022;283:114578. [PMID: 34464702 DOI: 10.1016/j.jep.2021.114578] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Ahmed AAQ, Qi F, Zheng R, Xiao L, Abdalla AME, Mao L, Bakadia BM, Liu L, Atta OM, Li X, Shi Z, Yang G. The impact of ExHp-CD (outer membrane vesicles) released from Helicobacter pylori SS1 on macrophage RAW 264.7 cells and their immunogenic potential. Life Sci 2021;279:119644. [PMID: 34048813 DOI: 10.1016/j.lfs.2021.119644] [Reference Citation Analysis]
167 Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT, Sáez K, García-Cancino A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021;10:382. [PMID: 33806815 DOI: 10.3390/pathogens10030382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Xie W, Zhao W, Zou Z, Kong L, Yang L. Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice. Helicobacter 2021;26. [DOI: 10.1111/hel.12807] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin North Am 2021;50:261-82. [PMID: 34024441 DOI: 10.1016/j.gtc.2021.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Zhao Y, Cai Y, Chen Z, Li H, Xu Z, Li W, Jia J, Sun Y. SpoT-mediated NapA upregulation promotes oxidative stress-induced Helicobacter pylori biofilm formation and confers multidrug resistance. Antimicrob Agents Chemother 2021:AAC. [PMID: 33649116 DOI: 10.1128/AAC.00152-21] [Reference Citation Analysis]
172 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
173 Kumar S, Sangitha R, Nachamkin I, Metz DC. Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley. GastroHep 2020;2:6-12. [PMID: 32377173 DOI: 10.1002/ygh2.382] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
174 Bilgilier C, Thannesberger J, Ojeda Cisneros M, Boehnke K, Wu J, Xi C, Bussalleu Rivera A, Steininger C. Antimicrobial Resistance of Helicobacter pylori in Gastric Biopsy Samples from Lima/Peru. Microb Drug Resist 2021;27:951-5. [PMID: 33085931 DOI: 10.1089/mdr.2020.0241] [Reference Citation Analysis]
175 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
176 Miftahussurur M, Waskito LA, Fauzia KA, Mahmudah I, Doohan D, Adnyana IK, Khomsan A, Ratnasari N, Rezkitha YAA. Overview of Helicobacter pylori Infection in Indonesia: What Distinguishes It from Countries with High Gastric Cancer Incidence? Gut Liver 2021;15:653-65. [PMID: 32616679 DOI: 10.5009/gnl20019] [Reference Citation Analysis]
177 Brennan DE, O'Morain C, McNamara D, Smith SM. Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success. World J Gastrointest Pathophysiol 2022; 13(1): 34-40 [DOI: 10.4291/wjgp.v13.i1.34] [Reference Citation Analysis]
178 Botija G, García Rodríguez C, Recio Linares A, Campelo Gutiérrez C, Pérez-Fernández E, Barrio Merino A. Antibiotic resistances and eradication rates in Helicobacter pylori infection. An Pediatr (Engl Ed) 2021;95:431-7. [PMID: 34810153 DOI: 10.1016/j.anpede.2020.10.010] [Reference Citation Analysis]
179 Güven B, Gülerman F, Kaçmaz B. Helicobacter pylori resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: A cross-sectional study. Helicobacter 2019;24:e12581. [PMID: 30950125 DOI: 10.1111/hel.12581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Jaka H, Mueller A, Kasang C, Mshana SE. Predictors of triple therapy treatment failure among H. pylori infected patients attending at a tertiary hospital in Northwest Tanzania: a prospective study. BMC Infect Dis 2019;19:447. [PMID: 31113384 DOI: 10.1186/s12879-019-4085-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
182 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
183 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Reference Citation Analysis]
184 Van den Poel B, Gils S, Micalessi I, Carton S, Christiaens P, Cuyle PJ, Moons V, Van Olmen G, Smismans A, Bourgain C, Bossuyt P, Frans J. Molecular detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies: a prospective evaluation of RIDA®GENE Helicobacter pylori assay. Acta Clin Belg 2021;76:177-83. [PMID: 31662122 DOI: 10.1080/17843286.2019.1685741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
185 Wu J, Zhu X, Guo X, Yang Z, Cai Q, Gu D, Luo W, Yuan C, Xiang Y. Helicobacter urease suppresses cytotoxic CD8 + T cell responses through activating Myh9-dependent induction of PD-L1. Int Immunol 2021:dxab044. [PMID: 34297096 DOI: 10.1093/intimm/dxab044] [Reference Citation Analysis]
186 Sharafutdinov I, Backert S, Tegtmeyer N. The Helicobacter pylori type IV secretion system upregulates epithelial cortactin expression by a CagA- and JNK-dependent pathway. Cell Microbiol 2021;:e13376. [PMID: 34197673 DOI: 10.1111/cmi.13376] [Reference Citation Analysis]
187 Zou PY, Hu J, Zhao JT, Zhao Z, Mei H, Yang J, Zhu YJ, Zhang Y, Lan CH. 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis. Helicobacter 2021;:e12833. [PMID: 34318966 DOI: 10.1111/hel.12833] [Reference Citation Analysis]
188 Zare Javid A, Maghsoumi-Norouzabad L, Bazyar H, Aghamohammadi V, Alavinejad P. Effects of Concurrent Omega-3 and Cranberry Juice Consumption Along with Standard Antibiotic Therapy on the Eradication of Helicobacter pylori, Gastrointestinal Symptoms, Some Serum Inflammatory and Oxidative Stress Markers in Adults with Helicobacter pylori Infection: A Study Protocol for a Randomized Controlled Trial. Infect Drug Resist 2020;13:3179-85. [PMID: 32982332 DOI: 10.2147/IDR.S270057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM;  Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093-2112. [PMID: 33004546 DOI: 10.1136/gutjnl-2020-322368] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
190 Zhumakanova BS, Korona-Głowniak I, Skalicka-Woźniak K, Ludwiczuk A, Baj T, Wojtanowski KK, Józefczyk A, Zhaparkulova KA, Sakipova ZB, Malm A. Phytochemical Fingerprinting and In Vitro Antimicrobial and Antioxidant Activity of the Aerial Parts of Thymus marschallianus Willd. and Thymus seravschanicus Klokov Growing Widely in Southern Kazakhstan. Molecules 2021;26:3193. [PMID: 34073499 DOI: 10.3390/molecules26113193] [Reference Citation Analysis]
191 O'Connor A, Liou JM, Gisbert JP, O'Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter 2019;24 Suppl 1:e12640. [PMID: 31486235 DOI: 10.1111/hel.12640] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
192 Sung JJY. Population-based screening and mass eradication of Helicobacter pylori infection to prevent gastric cancer: There are more questions than answers. J Gastroenterol Hepatol 2020;35:521-2. [PMID: 32285527 DOI: 10.1111/jgh.15024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019;12:909-915. [PMID: 31424296 DOI: 10.1080/17512433.2019.1654858] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
194 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
195 Rao X, Liu X, Liu N, Zhang Y, Zhang Z, Zhou L, Han G, Cen R, Shi N, Zhu H, Gong H, Huang C, Ji Q, Li Q. Long noncoding RNA NEAT1 promotes tumorigenesis in H. pylori gastric cancer by sponging miR-30a to regulate COX-2/BCL9 pathway. Helicobacter 2021;:e12847. [PMID: 34396632 DOI: 10.1111/hel.12847] [Reference Citation Analysis]
196 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Cao Y, Zhang J, Liu Y, Zhang L, Wang L, Wang J, Qi Y, Lv H, Liu J, Huo L, Wei X, Shi Y. The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial. Medicine (Baltimore) 2021;100:e27923. [PMID: 34918639 DOI: 10.1097/MD.0000000000027923] [Reference Citation Analysis]
198 Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [DOI: 10.1111/hel.12586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
199 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
200 Wu T, Wang L, Gong M, Lin Y, Xu Y, Ye L, Yu X, Liu J, Liu J, He S, Zeng H, Wang G. Synergistic effects of nanoparticle heating and amoxicillin on H. pylori inhibition. Journal of Magnetism and Magnetic Materials 2019;485:95-104. [DOI: 10.1016/j.jmmm.2019.04.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
202 Modak JK, Tikhomirova A, Gorrell RJ, Rahman MM, Kotsanas D, Korman TM, Garcia-Bustos J, Kwok T, Ferrero RL, Supuran CT, Roujeinikova A. Anti-Helicobacter pylori activity of ethoxzolamide. J Enzyme Inhib Med Chem 2019;34:1660-7. [PMID: 31530039 DOI: 10.1080/14756366.2019.1663416] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
203 Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol 2021. [PMID: 33691344 DOI: 10.1111/jgh.15468] [Reference Citation Analysis]
204 Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Reference Citation Analysis]
205 González-hormazábal P, Arenas A, Serrano C, Pizarro M, Fuentes-lópez E, Arnold J, Berger Z, Musleh M, Valladares H, Lanzarini E, Jara L, Castro VG, Camargo MC, Riquelme A. Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients. Archives of Medical Research 2021;52:529-34. [DOI: 10.1016/j.arcmed.2021.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Saracino IM, Pavoni M, Zullo A, Fiorini G, Lazzarotto T, Borghi C, Vaira D. Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review. Antibiotics (Basel) 2021;10:437. [PMID: 33919811 DOI: 10.3390/antibiotics10040437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
208 Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, Almadi M. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8. [PMID: 32295933 DOI: 10.4103/sjg.SJG_626_19] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
209 Domanovich-Asor T, Motro Y, Khalfin B, Craddock HA, Peretz A, Moran-Gilad J. Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in Helicobacter pylori. Microorganisms 2020;9:E2. [PMID: 33374988 DOI: 10.3390/microorganisms9010002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
210 Gao C, Zhang D, Zhang T, Wang J, Han S, Graham DY, Lu H. PPI‐amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta‐analysis. Helicobacter 2020;25. [DOI: 10.1111/hel.12692] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
211 Shakoor S, Platts-mills JA, Hasan R. Antibiotic-Resistant Enteric Infections. Infectious Disease Clinics of North America 2019;33:1105-23. [DOI: 10.1016/j.idc.2019.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
212 Murray BO, Dawson RA, Alsharaf LM, Anne Winter J. Protective effects of Helicobacter pylori membrane vesicles against stress and antimicrobial agents. Microbiology (Reading) 2020;166:751-8. [PMID: 32463354 DOI: 10.1099/mic.0.000934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
213 Vilaichone RK, Aumpan N, Ratanachu-Ek T, Uchida T, Tshering L, Mahachai V, Yamaoka Y. Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan. Int J Infect Dis 2020;97:102-7. [PMID: 32474200 DOI: 10.1016/j.ijid.2020.05.077] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Kobatake T, Ogino K, Sakae H, Gotoh K, Watanabe A, Matsushita O, Okada H, Yokota K. Antibacterial Effects of Disulfiram in Helicobacter pylori. Infect Drug Resist 2021;14:1757-64. [PMID: 34012274 DOI: 10.2147/IDR.S299177] [Reference Citation Analysis]
215 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
216 Zagari RM, Romano M, Frazzoni L, Marasco G, Dajti E, Arcidiacono PG, Armuzzi A, Biagi F, Cannizzaro R, Cavestro GM, Ciacci C, Monica F, Peralta S, Radaelli F, Bazzoli F. Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. Helicobacter 2021;:e12862. [PMID: 34766392 DOI: 10.1111/hel.12862] [Reference Citation Analysis]
217 Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules. 2020;25. [PMID: 32187986 DOI: 10.3390/molecules25061340] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 39.5] [Reference Citation Analysis]
218 Quinn L, Sheh A, Ellis JL, Smith DE, Booth SL, Fu X, Muthupalani S, Ge Z, Puglisi DA, Wang TC, Gonda TA, Holcombe H, Fox JG. Helicobacter pylori antibiotic eradication coupled with a chemically defined diet in INS-GAS mice triggers dysbiosis and vitamin K deficiency resulting in gastric hemorrhage. Gut Microbes 2020;11:820-41. [PMID: 31955643 DOI: 10.1080/19490976.2019.1710092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
219 Hathroubi S, Zerebinski J, Clarke A, Ottemann KM. Helicobacter pylori Biofilm Confers Antibiotic Tolerance in Part via A Protein-Dependent Mechanism. Antibiotics (Basel) 2020;9:E355. [PMID: 32599828 DOI: 10.3390/antibiotics9060355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
220 Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan. J Gastroenterol 2020;55:969-76. [DOI: 10.1007/s00535-020-01709-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
221 Zhang Y, Zhu Y, Zhao Z, Zhao J, Wang T, Yang J, Chen D, Lan C. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. European Journal of Gastroenterology & Hepatology 2020;32:563-8. [DOI: 10.1097/meg.0000000000001646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
222 Uddin R, Khalil W. A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori. Genes Genomics 2020;42:519-41. [PMID: 32193857 DOI: 10.1007/s13258-020-00921-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. World J Clin Cases 2022; 10(1): 227-235 [DOI: 10.12998/wjcc.v10.i1.227] [Reference Citation Analysis]
224 Singh H, Chung H, Awan I, Mone A, Cooper R, Patel S, Grigoryan Z, Ishida Y, Papachristou C, Judge T, DeSipio J, Phadtare S. Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.Helicobacter. 2021;26:e12769. [PMID: 33167084 DOI: 10.1111/hel.12769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K, Ludolph T, Meyer J, Miehlke S, Mohr A, Tüffers K, Usadel H, Wagner S, Wenzel H, Wiemer L, Vorreiter J, Eisele B, Hofreuter D, Glocker EO. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2020;26:235-9. [PMID: 31212078 DOI: 10.1016/j.cmi.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
227 Chen LW, Chang LC, Hua CC, Liu CJ, Chou TS, Lin CL, Chien RN. The Application of High-Dose Proton Pump Inhibitor Induction Treatment before Dual Therapy for Helicobacter pylori Eradication: An Open-Label Random Trial. J Clin Med 2021;10:4352. [PMID: 34640370 DOI: 10.3390/jcm10194352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. [Management of Helicobacter pylori infection in the pediatric age]. An Pediatr (Barc) 2021:S1695-4033(21)00202-2. [PMID: 34183279 DOI: 10.1016/j.anpedi.2021.05.014] [Reference Citation Analysis]
230 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Reference Citation Analysis]
231 Chen Z, Chen H, Yu L, Xin H, Kong J, Bai Y, Zeng W, Zhang J, Wu Q, Fan H. Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection. J Cell Physiol 2021;236:1158-83. [PMID: 32710499 DOI: 10.1002/jcp.29925] [Reference Citation Analysis]
232 Mokhtare M, Nikkhah M, Behnam B, Agah S, Bahardoust M, Masoodi M, Faghihi A. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with Helicobacter pylori infection. Indian J Pharmacol 2020;52:266-71. [PMID: 33078727 DOI: 10.4103/ijp.IJP_719_19] [Reference Citation Analysis]
233 Gisbert JP, Alcedo J, Amador J, Bujanda L, Calvet X, Castro-Fernández M, Fernández-Salazar L, Gené E, Lanas Á, Lucendo AJ, Molina-Infante J, Nyssen OP, Pérez-Aisa A, Puig I. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterol Hepatol 2021:S0210-5705(21)00229-6. [PMID: 34629204 DOI: 10.1016/j.gastrohep.2021.07.011] [Reference Citation Analysis]
234 Chen Y, Yuan H, Ye H, Shi Z, Deng X, Zhang X, Hou X. Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial. Microbiologyopen 2021;10:e1172. [PMID: 33650799 DOI: 10.1002/mbo3.1172] [Reference Citation Analysis]
235 Arslan M, Balamtekin N, Günal A. Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children. Helicobacter 2020;25:e12757. [PMID: 32939900 DOI: 10.1111/hel.12757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Giacobbe DR, Maraolo AE, Simeon V, Magnè F, Pace MC, Gentile I, Chiodini P, Viscoli C, Sanguinetti M, Mikulska M, Fiore M, Bassetti M. Changes in the relative prevalence of candidaemia due to non-albicans Candida species in adult in-patients: A systematic review, meta-analysis and meta-regression. Mycoses 2020;63:334-42. [PMID: 31997414 DOI: 10.1111/myc.13054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
238 Aumpan N, Vilaichone RK, Gamnarai P, Sanglutong L, Ratanachu-Ek T, Mahachai V, Yamaoka Y. Prevalence and Antibiotic Resistance Patterns of Helicobacter pylori Infection in Koh Kong, Cambodia. Asian Pac J Cancer Prev 2020;21:1409-13. [PMID: 32458649 DOI: 10.31557/APJCP.2020.21.5.1409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Sukri A, Lopes BS, Hanafiah A. The Emergence of Multidrug-Resistant Helicobacter pylori in Southeast Asia: A Systematic Review on the Trends and Intervention Strategies Using Antimicrobial Peptides. Antibiotics (Basel) 2021;10:1061. [PMID: 34572643 DOI: 10.3390/antibiotics10091061] [Reference Citation Analysis]
240 Rojas García P, van der Pol S, van Asselt ADI, Postma M, Rodríguez-Ibeas R, Juárez-Castelló CA, González M, Antoñanzas F. Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review. Antibiotics (Basel) 2021;10:55. [PMID: 33430005 DOI: 10.3390/antibiotics10010055] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Fong P, Hao CH, Io CC, Sin PI, Meng LR. In Silico and In Vitro Anti-Helicobacter Pylori Effects of Combinations of Phytochemicals and Antibiotics. Molecules 2019;24:E3608. [PMID: 31591315 DOI: 10.3390/molecules24193608] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
242 Jiang Y, Chen Y, Song Z, Tan Z, Cheng J. Recent advances in design of antimicrobial peptides and polypeptides toward clinical translation. Adv Drug Deliv Rev 2021;170:261-80. [PMID: 33400958 DOI: 10.1016/j.addr.2020.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
243 Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14‐day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first‐line Helicobacter pylori infection eradication: A randomized trial. Helicobacter 2020;25. [DOI: 10.1111/hel.12762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
245 Tehlan A, Karmakar BC, Paul S, Kumar R, Kaur I, Ghosh A, Mukhopadhyay AK, Dhar SK. Antibacterial action of acriflavine hydrochloride for eradication of the gastric pathogen Helicobacter pylori. FEMS Microbiol Lett 2020;367:fnaa178. [PMID: 33118020 DOI: 10.1093/femsle/fnaa178] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
246 Ouyang Y, Zhu Z, Huang L, Zeng C, Zhang L, Wu WK, Lu N, Xie C. Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020. Helicobacter 2021;:e12835. [PMID: 34258827 DOI: 10.1111/hel.12835] [Reference Citation Analysis]
247 Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, Vlachou E, Tsibouris P, Alexandrakis G. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol 2020;54:522-7. [PMID: 32028286 DOI: 10.1097/MCG.0000000000001328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
248 Pichon M, Tran CT, Motillon G, Debiais C, Gautier S, Aballea M, Cremniter J, Vasseur P, Tougeron D, Garcia M, Garnier M, Bodet C, Faure JP, Burucoa C. Where to Biopsy to Detect Helicobacter pylori and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach. J Clin Med 2020;9:E2812. [PMID: 32878081 DOI: 10.3390/jcm9092812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
249 Salehi N, Attaran B, Eskini N, Esmaeili M, Sharifirad A, Sadeghi M, Mohammadi M. New insights into resistance of Helicobacter pylori against third‐ and fourth‐generation fluoroquinolones: A molecular docking study of prevalent GyrA mutations. Helicobacter 2019;24. [DOI: 10.1111/hel.12628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
250 Silvan JM, Gutiérrez-Docio A, Moreno-Fernandez S, Alarcón-Cavero T, Prodanov M, Martinez-Rodriguez AJ. Procyanidin-Rich Extract from Grape Seeds as a Putative Tool against Helicobacter pylori. Foods 2020;9:E1370. [PMID: 32993186 DOI: 10.3390/foods9101370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
251 Carlson TJ, Gonzales-Luna AJ, Garey KW. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol 2021;37:30-6. [PMID: 33229860 DOI: 10.1097/MOG.0000000000000696] [Reference Citation Analysis]
252 Keough DT, Wun SJ, Baszczyňski O, Eng WS, Špaček P, Panjikar S, Naesens L, Pohl R, Rejman D, Hocková D, Ferrero RL, Guddat LW. Helicobacter pylori Xanthine-Guanine-Hypoxanthine Phosphoribosyltransferase-A Putative Target for Drug Discovery against Gastrointestinal Tract Infections. J Med Chem 2021;64:5710-29. [PMID: 33891818 DOI: 10.1021/acs.jmedchem.0c02184] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Zhu S, Khalafi S, Chen Z, Poveda J, Peng D, Lu H, Soutto M, Que J, Garcia-Buitrago M, Zaika A, El-Rifai W. Silencing of miR490-3p by H. pylori activates DARPP-32 and induces resistance to gefitinib. Cancer Lett 2020;491:87-96. [PMID: 32735911 DOI: 10.1016/j.canlet.2020.07.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Darmani H, Smadi EAM, Bataineh SMB. Blue light emitting diodes enhance the antivirulence effects of Curcumin against Helicobacter pylori. J Med Microbiol 2020;69:617-24. [PMID: 32100708 DOI: 10.1099/jmm.0.001168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
255 Jia J, Zhang C, Liu Y, Huang Y, Bai Y, Hang X, Zeng L, Zhu D, Bi H. Armeniaspirol A: a novel anti-Helicobacter pylori agent. Microb Biotechnol 2021. [PMID: 33780131 DOI: 10.1111/1751-7915.13807] [Reference Citation Analysis]
256 Li Y, Lin R, Jin Y, Jin S, Chen B, Wu X. Genotyping Helicobacter pylori antibiotic resistance - and virulence-associated genes in patients with gastric cancer in Wenzhou, China. Arab J Gastroenterol 2021:S1687-1979(21)00039-3. [PMID: 34120851 DOI: 10.1016/j.ajg.2021.05.017] [Reference Citation Analysis]
257 Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol 2021;12:e00391. [PMID: 34397042 DOI: 10.14309/ctg.0000000000000391] [Reference Citation Analysis]
258 Zuo NY, Zhang YD, Dong QW, Bi J, Liu X. Effect of Anti-Hp treatment on nutritional status of children with Helicobacter Pylori-Positive Gastritis and its clinical significance. Pak J Med Sci 2021;37:1430-4. [PMID: 34475925 DOI: 10.12669/pjms.37.5.4234] [Reference Citation Analysis]
259 Puah SM, Goh KL, Ng HK, Chua KH. Current status of Helicobacter pylori resistance to Clarithromycin and Levofloxacin in Malaysia-findings from a molecular based study. PeerJ 2021;9:e11518. [PMID: 34178444 DOI: 10.7717/peerj.11518] [Reference Citation Analysis]
260 Khademi F, Sahebkar A. An Updated Systematic Review and Meta-Analysis on the Helicobacter pylori Antibiotic Resistance in Iran (2010-2020). Microb Drug Resist 2020;26:1186-94. [PMID: 32354289 DOI: 10.1089/mdr.2020.0088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
261 Attaran B, Salehi N, Ghadiri B, Esmaeili M, Kalateh S, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The penicillin binding protein 1A of Helicobacter pylori, its amoxicillin binding site and access routes. Gut Pathog 2021;13:43. [PMID: 34183046 DOI: 10.1186/s13099-021-00438-0] [Reference Citation Analysis]
262 Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA. Dig Dis Sci. 2019;64:2893-2898. [PMID: 31187323 DOI: 10.1007/s10620-019-05694-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
263 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Pathogens 2019;8:E228. [PMID: 31717683 DOI: 10.3390/pathogens8040228] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
264 Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Reference Citation Analysis]
265 Shen X, Zhang W, Peng C, Yan J, Chen P, Jiang C, Yuan Y, Chen D, Zhu W, Yao M. In vitro anti-bacterial activity and network pharmacology analysis of Sanguisorba officinalis L. against Helicobacter pylori infection. Chin Med 2021;16:33. [PMID: 33865425 DOI: 10.1186/s13020-021-00442-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Siriviriyakul P, Werawatganon D, Phetnoo N, Somanawat K, Chatsuwan T, Klaikeaw N, Chayanupatkul M. Genistein attenuated gastric inflammation and apoptosis in Helicobacter pylori-induced gastropathy in rats. BMC Gastroenterol 2020;20:410. [PMID: 33297977 DOI: 10.1186/s12876-020-01555-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
267 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira D. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics (Basel) 2020;9:E121. [PMID: 32183165 DOI: 10.3390/antibiotics9030121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
268 Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T, Bordin D, Smith S, Lamy V, Caldas M, Resina E, Muñoz R, Cosme Á, Puig I, Megraud F, O'Morain C, Gisbert JP; The Hp-EuReg Investigators. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel) 2021;10:1058. [PMID: 34572640 DOI: 10.3390/antibiotics10091058] [Reference Citation Analysis]
269 Salillas S, Alías M, Michel V, Mahía A, Lucía A, Rodrigues L, Bueno J, Galano-frutos JJ, De Reuse H, Velázquez-campoy A, Carrodeguas JA, Sostres C, Castillo J, Aínsa JA, Díaz-de-villegas MD, Lanas Á, Touati E, Sancho J. Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori -Infected Mice. J Med Chem 2019;62:6102-15. [DOI: 10.1021/acs.jmedchem.9b00355] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]